New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
“Given his general management and commercial experience, we are confident that Per is the right person to lead us through the next phases of development,” says Chairman of the Board Göran Lerenius, who continues:
“Through this appointment PharmNovo is strengthening the organisation on both the scientific and commercial sides, whilst maintaining full focus on the continued pre-clinical development.
The company’s founder and former CEO, Bengt von Mentzer, remains critical to PharmNovo´s business activities and will now focus even more of his time and efforts on the PN6047 development and the upcoming Regulatory Toxicology programme.
At the Extraordinary General Meeting held in May at Medicon Village, Lund, Sweden, Chairman of the Board Göran Lerenius thanked Bengt for founding the company and for leading it successfully over many years.
New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
“Given his general management and commercial experience, we are confident that Per is the right person to lead us through the next phases of development,” says Chairman of the Board Göran Lerenius, who continues:
“Through this appointment PharmNovo is strengthening the organisation on both the scientific and commercial sides, whilst maintaining full focus on the continued pre-clinical development.
The company’s founder and former CEO, Bengt von Mentzer, remains critical to PharmNovo´s business activities and will now focus even more of his time and efforts on the PN6047 development and the upcoming Regulatory Toxicology programme.
At the Extraordinary General Meeting held in May at Medicon Village, Lund, Sweden, Chairman of the Board Göran Lerenius thanked Bengt for founding the company and for leading it successfully over many years.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
